For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.

Only RUKOBIA protects CD4 by directly targeting gp120

PREVENTS
HIV-1 from attaching to
host immune cells1
TARGETS
both circulating soluble
and viral-bound gp1201
PROTECTS
CD4+ T-cells, leaving healthy, uninfected cells untouched1
  • Temsavir, the active moiety of RUKOBIA, attaches directly to gp120 on the surface of HIV-1 virions, near the CD4 attachment site.2 The attachment of temsavir locks gp120 into a closed formation that prevents the initial interaction between the virus and host immune cells
  • This action prevents the first step of viral entry3
  • No cross-resistance with other ARVs

Learn more about RUKOBIA in the BRIGHTE Trial

Read more »

ARV=antiretroviral; gp120=glycoprotein 120.

References:

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated September 21, 2022. Accessed September 20, 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adultadolescent-arv/guidelines-adult-adolescent-arv.pdf
  2. Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223.
  3. Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.

References:

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated September 21, 2022. Accessed September 20, 2022. https://clinicalinfo.hiv.gov/sites/default/files/
    guidelines/documents/adultadolescent-arv/
    guidelines-adult-adolescent-arv.pdf
  2. Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223.
  3. Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.

FSTWCNT220023